A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
Key Details
- 1The Path-IO model uses AI to analyze digital pathology slides from NSCLC patients.
- 2Tested on 797 patients (MD Anderson) and validated on 280 international patients (including Lung-MAP S1400I trial).
- 3The model stratified patients into high- and low-risk groups, doubling risk in the high-risk cohort.
- 4Path-IO outperformed PD-L1 biomarker: Path-IO C-indices up to 0.69 (OS) and 0.65 (PFS); PD-L1 indices as low as 0.50-0.58.
- 5Integrating radiomics and clinical data improved prediction performance further (C-index for OS to 0.75, PFS to 0.70).
- 6Study validated across real-world and phase III trial cohorts, though retrospective; prospective validation is the next step.
Why It Matters
This work demonstrates that advanced AI analysis of digital pathology can outperform traditional biomarkers in predicting immunotherapy outcomes. If validated further, such tools could help personalize treatment for cancer patients, offering a significant advance in precision oncology and imaging AI.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.